Expression of TGFβ-1 and EHD1 correlated with survival of non-small cell Lung cancer
- 228 Downloads
Transforming growth factor-β1 (TGFβ-1) signaling is regulated by endocytotic pathway. To clarify the prognostic value of TGFβ-1 and to verify the involvement of endocytosis in drug resistance, we examined the expression of TGFβ-1 and Eps15 homology domain 1 (EHD1) in non-small cell lung cancer (NSCLC) and its association with tumor characteristics and survival of patients with NSCLC. Expression of TGFβ-1 and EHD1 was evaluated by immunohistochemistry in paraffin sections from 105 NSCLC patients. Overall survival (OS) was analyzed by Kaplan–Meier method, log-rank test, and multivariate Cox proportional hazard regression model. Positive immunostaining of TGFβ-1 and EHD1 was detected in 52.38 and 39.05 % of NSCLC samples, respectively. In non-adjuvant chemotherapy-treated group (P = 0.006) and epidermal growth factor receptor (EGFR) (+) group (P = 0.038), patients with TGFβ-1 expression had a longer OS. EHD1 negative expression predicted a longer OS (P = 0.003), especially in EGFR (+) (P = 0.006) and adjuvant chemotherapy-treated patients (P = 0.003). NSCLC patients with concurrent positive TGFβ-1 and negative EHD1 (combined markers) were significantly correlated with better OS (P = 0.001). American Joint Committee on Cancer (AJCC) status and combined markers were independent prognostic indicators for OS (HR (95 % CI) 1.576 (1.112–2.232), P = 0.011 and HR 0.349 (0.180–0.673), P = 0.002, respectively). We identified concordant TGFβ-1 positive and EHD1 negative as a strong favorable prognosis factor in NSCLC. Our results may help us to select and optimize strategies for individualized therapy.
KeywordsTGFβ-1 EHD1 Survival Non-small cell lung cancer (NSCLC)
Eps15 homology domain 1
Non-small cell lung cancer
Transforming growth factor-β1
Median survival time
Thanks are given to Professor Jin Xiaoming and Dr. Tong Dandan for providing pathologic evaluation.
This work was supported by the National Natural and by Natural Science Foundation of Heilongjiang Province, China (grant number: LC2012C08 to M.Q.) Science Foundation of China (grant number 30772540, 81172214 to L.C.).
Conflicts of interest
- 24.Caplan S, Naslavsky N, Hartnell LM, Lodge R, Polishchuk RS, Donaldson JG, et al. A tubular EHD1-containing compartment involved in the recycling of major histocompatibility complex class I molecules to the plasma membrane. EMBO J. 2002;21(11):2557–67. doi: 10.1093/emboj/21.11.2557.PubMedCentralCrossRefPubMedGoogle Scholar
- 26.Bennett WP, El-Deiry WS, Rush WL, Guinee Jr DG, Freedman AN, Caporaso NE, et al. p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 1998;4(6):1499–506.Google Scholar
- 29.Jansen FH, Krijgsveld J, van Rijswijk A, van den Bemd GJ, van den Berg MS, van Weerden WM, et al. Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins. Molecular Cellular Proteomics: MCP. 2009;8(6):1192–205. doi: 10.1074/mcp.M800443-MCP200.PubMedCentralCrossRefPubMedGoogle Scholar